ANORMED AMENDS LICENSE AGREEMENT FOR CANCER DRUG

AnorMED Inc. today announced it will receive U.S. $10 million in cash in consideration for amending the license agreement for its proprietary anti-cancer drug picoplatin (NX473) to expand the licensed territories to worldwide, forego future development milestones and reduce royalty payments. Yahoo Finance (http://biz.yahoo.com/prnews/060919/to332.html?.v=5)